stockrowRoyalty Pharma PLC
RPRX Healthcare Biotechnology
Royalty Pharma PLC’s revenue for fiscal 2025 (year ended December 2025) was $2.4 billion, up 5.06% from fiscal 2024.
- Revenue
- +13.3%
- EPS
- −51.5%
- Free cash flow
- +364.6%
- Total debt
- −4.00%
Quarter to September 2026, against a year earlier
Follow RPRX
Alert me
Royalty Pharma PLC (RPRX) Shares outstanding
Royalty Pharma PLC's shares outstanding at the end of fiscal 2025 was $564.5M, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $557.0M. Over the past ten years it has ranged from $375.5M (fiscal 2020) to $602.9M (fiscal 2023); the current reading is higher than 71% of that period. Royalty Pharma PLC ranks 8th of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $564.5M | (4.99%) |
| FY2024 | $594.1M | (1.46%) |
| FY2023 | $602.9M | 37.66% |
| FY2022 | $438.0M | 5.59% |
| FY2021 | $414.8M | 10.48% |
| FY2020 | $375.5M | 0.00% |
| FY2019 | $375.5M | — |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $557.0M | 0.02% |
| Jun 2026 | $556.9M | 0.01% |
| Mar 2026 | $556.8M | (1.35%) |
| Dec 2025 | $564.5M | 0.87% |
| 22 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| ROIV Roivant Sciences Ltd. compare | $720.8M |
| GMAB Genmab A/S Sponsored ADR compare | $617.1M |
| RPRX Royalty Pharma PLC | $557.0M |
| BNTX BioNTech SE Sponsored ADR compare | $252.7M |
| INSM Insmed, Inc. compare | $218.8M |
| RVMD Revolution Medicines, Inc. compare | $214.9M |
| INCY Incyte Corporation compare | $203.2M |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $115.8M |
| ARGX argenex SE compare | $64.9M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on RPRX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement